Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CXCR5 | P32302 | 4/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.39 |
| ▸ | CETP | P11597 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 5/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.36 |
| ▸ | UGCG | Q16739 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899579 | 1.00 | CTSL (0.40) | CTSLCXCR5PSMB5CETPBACE1 | |
| SCHEMBL1898616 | 0.93 | CTSL (0.44) | CTSLCXCR5PSMB5CETPUGCG | |
| SCHEMBL1901640 | 0.87 | CETP (0.36) | CETPBACE1BACE2UGCG | |
| SCHEMBL1901641 | 0.87 | CETP (0.36) | CETPBACE1BACE2UGCG | |
| SCHEMBL1899264 | 0.87 | CTSL (0.38) | CTSLCXCR5PSMB5CETPBACE1 | |
| SCHEMBL5751530 | 0.86 | CETP (0.35) | CETPBACE1BACE2UGCGSCN9A | |
| SCHEMBL5752767 | 0.86 | CETP (0.35) | CETPBACE1BACE2UGCGSCN9A | |
| SCHEMBL5751746 | 0.85 | SCN9A (0.36) | CETPBACE1BACE2UGCGSCN9A | |
| SCHEMBL1897534 | 0.84 | CETP (0.36) | CETPBACE1UGCGSCN9A | |
| SCHEMBL5751394 | 0.83 | CXCR5 (0.46) | CTSLCXCR5PSMB5BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CTSL 452/4885CXCR5 3335/4885PSMB5 470/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CTSL 452/4885CXCR5 3335/4885PSMB5 470/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CTSL 1252/4885CXCR5 3681/4885PSMB5 3173/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CTSL 452/4885CXCR5 3335/4885PSMB5 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.